252 related articles for article (PubMed ID: 1693076)
1. Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides.
Nilsson B; Nilsson Ekdahl K; Avila D; Nilsson UR; Lambris JD
Biochem J; 1990 May; 268(1):55-61. PubMed ID: 1693076
[TBL] [Abstract][Full Text] [Related]
2. Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression.
Nilsson B; Grossberger D; Nilsson Ekdahl K; Riegert P; Becherer DJ; Nilsson UR; Lambris JD
Biochem J; 1992 Mar; 282 ( Pt 3)(Pt 3):715-21. PubMed ID: 1372802
[TBL] [Abstract][Full Text] [Related]
3. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
[TBL] [Abstract][Full Text] [Related]
4. Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments.
Nilsson B; Svensson KE; Borwell P; Nilsson UR
Mol Immunol; 1987 May; 24(5):487-94. PubMed ID: 2443836
[TBL] [Abstract][Full Text] [Related]
5. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
[TBL] [Abstract][Full Text] [Related]
6. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies.
Hack CE; Paardekooper J; Smeenk RJ; Abbink J; Eerenberg AJ; Nuijens JH
J Immunol; 1988 Sep; 141(5):1602-9. PubMed ID: 2457622
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
9. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
[TBL] [Abstract][Full Text] [Related]
10. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
Garred P; Mollnes TE; Lea T; Fischer E
Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
[TBL] [Abstract][Full Text] [Related]
12. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
[TBL] [Abstract][Full Text] [Related]
13. Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.
Meuth JL; Morgan EL; DiSipio RG; Hugli TE
J Immunol; 1983 Jun; 130(6):2605-11. PubMed ID: 6602172
[TBL] [Abstract][Full Text] [Related]
14. Distinctive expression of neoantigenic C3(D) epitopes on bound C3 following activation and binding to different target surfaces in normal and pathological human sera.
Nilsson B; Ekdahl KN; Svensson KE; Bjelle A; Nilsson UR
Mol Immunol; 1989 Apr; 26(4):383-90. PubMed ID: 2469949
[TBL] [Abstract][Full Text] [Related]
15. Characterization of three monoclonal antibodies against C3 with selective specificities.
Iida K; Mitomo K; Fujita T; Tamura N
Immunology; 1987 Nov; 62(3):413-7. PubMed ID: 2444528
[TBL] [Abstract][Full Text] [Related]
16. Identification of the C3b receptor-binding domain in third component of complement.
Becherer JD; Lambris JD
J Biol Chem; 1988 Oct; 263(28):14586-91. PubMed ID: 2971659
[TBL] [Abstract][Full Text] [Related]
17. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
Lachmann PJ; Pangburn MK; Oldroyd RG
J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
[TBL] [Abstract][Full Text] [Related]
18. Epitope characterization by modifications of antigens and by mapping on resin-bound peptides. Discriminating epitopes near the C-terminus and N-terminus of Escherichia coli ribosomal protein S13.
Syu WJ; Kahan L
J Immunol Methods; 1989 Mar; 118(2):153-60. PubMed ID: 2466901
[TBL] [Abstract][Full Text] [Related]
19. Two conformational forms of target-bound iC3b that distinctively bind complement receptors 1 and 2 and two specific monoclonal antibodies.
Nilsson UR; Funke L; Nilsson B; Ekdahl KN
Ups J Med Sci; 2011 Mar; 116(1):26-33. PubMed ID: 21070093
[TBL] [Abstract][Full Text] [Related]
20. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential.
Burger R; Zilow G; Bader A; Friedlein A; Naser W
J Immunol; 1988 Jul; 141(2):553-8. PubMed ID: 2454995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
